The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
The NCI60 human tumour cell line anticancer drug screen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationAlley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082
Self-citationScudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A. P., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. A., & Boyd, M. R. (1988) · PubMed · Cited by 2,342
Self-citationSystematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Boyd, M. R., & Paull, K. D. (1995) · Drug Development Research · doi:10.1002/ddr.430340203 · Cited by 1,572
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor
Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D., et al. (1998) · Science · doi:10.1126/science.280.5364.734 · Cited by 1,008
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationVistica, D. T., Skehan, P., Scudiero, D. A., Monks, A. P., Pittman, A. F., & Boyd, M. R. (1991) · PubMed · Cited by 745
Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H., & Boyd, M. R. (1989) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.577 · Cited by 685
Self-citationPredicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 483
Gazdar, A. F., Carney, D. N., Nau, M. M., & Minna, J. D. (1985) · PubMed · Cited by 477
(2002) · PubMed · Cited by 457
Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
Bai, R. L., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., & Hamel, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98491-7 · Cited by 379
In vivo cultivation of tumor cells in hollow fibers
Hollingshead, M. G., Alley, M. C., Camalier, R. F., Abbott, B. J., Mayo, J. G., Malspeis, L., & Grever, M. R. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00254-4 · Cited by 344
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Gazdar, A. F., Carney, D. N., RUSSELL, E. K., Sims, H. L., Baylin, S. B., Bunn, P. A., Guccion, J. G., & Minna, J. D. (1980) · PubMed · Cited by 316
Karyotypic complexity of the NCI-60 drug-screening panel.
Roschke, A. V., Tonon, G., Gehlhaus, K., Mctyre, N., Bussey, K. J., Lababidi, S., Scudiero, D. A., Weinstein, J. N., & Kirsch, I. R. (2003) · PubMed · Cited by 316
Neural Computing in Cancer Drug Development: Predicting Mechanism of Action
Weinstein, J. N., Kohn, K. W., Grever, M. R., Viswanadhan, V. N., Rubinstein, L. V., Monks, A. P., Scudiero, D. A., Welch, L., Koutsoukos, A. D., Chiausa, A. J., et al. (1992) · Science · doi:10.1126/science.1411538 · Cited by 312
NCI-navy medical oncology branch cell line data base
Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., McClintock, P. R., Linnoila, R. I., Matthews, M. J., Bunn, P. A., Carney, D., et al. (1996) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240630505 · Cited by 303
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Self-citationSalicylihalamides A and B, Novel Cytotoxic Macrolides from the Marine Sponge Haliclona sp.
Erickson, K. L., Beutler, J. A., Cardellina, J. H., & Boyd, M. R. (1997) · The Journal of Organic Chemistry · doi:10.1021/jo971556g · Cited by 255
Dan, S., Tsunoda, T., Kitahara, O., et al. (2002) · PubMed · Cited by 246
Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
Selwood, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602070 · Cited by 238
Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., & Fojo, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117910 · Cited by 216
Banded Marker Chromosomes as Indicators of Intraspecies Cellular Contamination
Nelson-Rees, W. A., Flandermeyer, R. R., & Hawthorne, P. K. (1974) · Science · doi:10.1126/science.184.4141.1093 · Cited by 210
Proteasome inhibition in cancer: Development of PS-341
ADAMS, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90034-x · Cited by 209
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Monks, A. P., Da, S., Johnson, G. S., Paull, K. D., & Sausville, E. (1997) · PubMed · Cited by 171
Further evidence to support the melanocytic origin of MDA-MB-435
Ellison, G. (2002) · Molecular Pathology · doi:10.1136/mp.55.5.294 · Cited by 164
Wu, L., Smythe, A. M., Stinson, S. F., Mullendore, L. A., Monks, A., Scudiero, D. A., Paull, K. D., Koutsoukos, A. D., Rubinstein, L., & Boyd, M. R. (1992) · PubMed · Cited by 156
The synthesis of XTT: A new tetrazolium reagent that is bioreducible to a water‐soluble formazan
Paull, K. D., Shoemaker, R. H., Boyd, M. R., Parsons, J. L., Risbood, P. A., Barbera, W. A., Sharma, M. N., Baker, D. C., Hand, E., Scudiero, D. A., et al. (1988) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570250340 · Cited by 156
Self-citationNaasani, I., Seimiya, H., Yamori, T., & TSURUO, T. (1999) · PubMed · Cited by 155
Anthrax Lethal Factor Proteolysis and Inactivation of MAPK Kinase
Chopra, A. P., Boone, S. A., Liang, X., & Duesbery, N. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211262200 · Cited by 151
Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., & Bowman, E. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29517-3 · Cited by 150
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics
Yamori, T. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0649-1 · Cited by 146
Rabow, A. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010385b · Cited by 141
Self-citationIdentification of small molecule inhibitors of anthrax lethal factor
Panchal, R. G., Hermone, A. R., Nguyen, T. L., Wong, T. Y., Schwarzenbacher, R., Schmidt, J. J., Lane, D. J., McGrath, C. F., Turk, B. E., Burnett, J. C., et al. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsmb711 · Cited by 136
Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval
(1997) · Humana Press eBooks · doi:10.1007/978-1-4615-8152-9 · Cited by 132
Anticancer Specificity of Some Ellipticinium Salts against Human Brain Tumors in vitro
Acton, E. M., Narayanan, V. L., Risbood, P. A., Shoemaker, R. H., Vistica, D. T., & Boyd, M. R. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00040a010 · Cited by 126
Self-citationStinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J., & Boyd, M. R. (1992) · PubMed · Cited by 119
Cruz‐Monserrate, Z., Vervoort, H. C., Bai, R., Newman, D. J., Howell, S. B., Los, G., Mullaney, J. T., Williams, M. D., Pettit, G. R., Fenical, W., et al. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1273 · Cited by 117
Nelson‐Rees, W. A., & Flandermeyer, R. R. (1977) · Science · doi:10.1126/science.557237 · Cited by 113
Xie, X., Padrón, D., Liao, X., Wang, J., Roth, M. G., & Brabander, J. K. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313796200 · Cited by 113
Fuller, R. W., Cardellina, J. H., Jurek, J., Scheuer, P. J., Alvarado-Lindner, B., McGuire, M., Gray, G. N., Steiner, J. R., Clardy, J., & Menez, E. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00051a019 · Cited by 107
Development of human tumor cell line panels for use in disease-oriented drug screening.
Shoemaker, R. H., Monks, A. P., Alley, M. C., Scudiero, D. A., Fine, D. L., McLemore, T. L., Abbott, B. J., Paull, K. D., Mayo, J. G., & Boyd, M. R. (1988) · PubMed · Cited by 106
Self-citationCell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen
Scudiero, D. A., Monks, A. P., & Sausville, E. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.862 · Cited by 101
Immune-deficient animals in biomedical research
Rygaard, J., Brunner, N. A., Groem, N., & Spang‐Thomsen, M. (1987) · Medical Entomology and Zoology · Cited by 94
Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic Agents
van Osdol, W. W., Myers, T. G., Paull, K. D., Kohn, K. W., & Weinstein, J. N. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.24.1853 · Cited by 85
Nakatsu, N., Yoshida, Y., Yamazaki, K., Nakamura, T., Dan, S., Fukui, Y., & Yamori, T. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0234 · Cited by 76
Structurally simplified macrolactone analogues of halichondrin B
Seletsky, B. M., Wang, Y., Hawkins, L. D., Palme, M. H., Habgood, G. J., DiPietro, L., Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.068 · Cited by 71
The Psammaplysenes, Specific Inhibitors of FOXO1a Nuclear Export
Schroeder, F. C., Kau, T. R., Silver, P. A., & Clardy, J. (2005) · Journal of Natural Products · doi:10.1021/np049624z · Cited by 61
Wallqvist, A., Rabow, A. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2002) · PubMed · Cited by 51
Self-citationAnthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase
Duesbery, N. S., & Woude, G. F. V. (1999) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.1999.00892.x · Cited by 46
Keskin, Ö., Bahar, I., Jernigan, R. L., Beutler, J. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2000) · PubMed · Cited by 45
Self-citationWallqvist, A., Rabow, A. A., Shoemaker, R. H., Sausville, E. A., & Covell, D. G. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg302 · Cited by 32
Self-citationBodart, J., Chopra, A., Liang, X., & Duesbery, N. S. (2002) · Cell Cycle · doi:10.4161/cc.1.1.95 · Cited by 28
The NCI Human Tumor Cell Line (60-Cell) Screen
Boyd, M. R. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-739-0_3 · Cited by 26
The identification and monitoring of cell line specificity.
Wa, N.-R. (1978) · PubMed · Cited by 24
Arguello, F., Alexander, M. A., Stinson, S. F., Jorden, J. L., Smith, E. M., Kalavar, N. T., Alvord, W. G., Klabansky, R. L., Greene, J. F., & Sausville, E. A. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050128 · Cited by 20
The Proteasome and the COMPARE Algorithm
Holbeck, S. L., & Sausville, E. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-794-9_8 · Cited by 6
Cited by
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation
Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A. L., Kafri, R., Kirschner, M. W., Clish, C. B., & Mootha, V. K. (2012) · Science · doi:10.1126/science.1218595 · Cited by 1,403
Natural product discovery: past, present, and future
Katz, L., & Baltz, R. H. (2016) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-015-1723-5 · Cited by 1,144
Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
Shimada, K., Skouta, R., Kaplan, A., Yang, W. S., Hayano, M., Dixon, S. J., Brown, L. M., Valenzuela, C. A., Wolpaw, A. J., & Stockwell, B. R. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2079 · Cited by 1,017
Metadata
- Authors
- Shoemaker, R. H.
- Venue
- Nature Reviews Cancer
- Published
- 2006-10-01
- Volume
- 6
- Issue
- 10
- Pages
- 813-823
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2087312216
- Cited by
- 2,620
- References
- 70
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.